CorePlus Collaborates with AIxMED Providing 100% QC on Bladder Cancer Detection with AI
SAN JUAN, Puerto Rico, Jan. 7, 2026 /PRNewswire/ -- CorePlus announced the implementation of AIxURO, a state-of-the-art software solution that...
Diagnostics
CorePlus Collaborates with AIxMED Providing 100% QC on Bladder Cancer Detection with AI
SAN JUAN, Puerto Rico, Jan. 7, 2026 /PRNewswire/ -- CorePlus announced the implementation of AIxURO, a state-of-the-art software solution that...
CorePlus Collaborates with AIxMED Providing 100% QC on Bladder Cancer Detection with AI
SAN JUAN, Puerto Rico, Jan. 7, 2026 /PRNewswire/ -- CorePlus announced the implementation of AIxURO, a state-of-the-art software solution that...
Alps Dx Launches to Modernize Oral Fluid Drug Testing Through Connected Pre-Analytical Automation
RICHMOND, Va., Jan. 7, 2026 /PRNewswire/ -- Alps Dx today announced its official launch as an innovative diagnostics tooling and...
Alps Dx Launches to Modernize Oral Fluid Drug Testing Through Connected Pre-Analytical Automation
RICHMOND, Va., Jan. 7, 2026 /PRNewswire/ -- Alps Dx today announced its official launch as an innovative diagnostics tooling and...
Alps Dx Launches to Modernize Oral Fluid Drug Testing Through Connected Pre-Analytical Automation
RICHMOND, Va., Jan. 7, 2026 /PRNewswire/ -- Alps Dx today announced its official launch as an innovative diagnostics tooling and...
InterVenn Biosciences Partners with Aranscia to Accelerate Commercialization of GlycoKnow™ Non-Invasive Ovarian Cancer Diagnostic Test
Aranscia's Suite of Laboratory and Technology Solutions to Support InterVenn's Commercialization ProgramSOUTH SAN FRANCISCO, Calif. and HOUSTON, Jan. 7, 2026...
InterVenn Biosciences Partners with Aranscia to Accelerate Commercialization of GlycoKnow™ Non-Invasive Ovarian Cancer Diagnostic Test
Aranscia's Suite of Laboratory and Technology Solutions to Support InterVenn's Commercialization ProgramSOUTH SAN FRANCISCO, Calif. and HOUSTON, Jan. 7, 2026...
InterVenn Biosciences Partners with Aranscia to Accelerate Commercialization of GlycoKnow™ Non-Invasive Ovarian Cancer Diagnostic Test
Aranscia's Suite of Laboratory and Technology Solutions to Support InterVenn's Commercialization ProgramSOUTH SAN FRANCISCO, Calif. and HOUSTON, Jan. 7, 2026...
Baird Medical Secures Regulatory Approvals in Pakistan and Vietnam
NEW YORK, Jan. 7, 2026 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a...
Baird Medical Secures Regulatory Approvals in Pakistan and Vietnam
NEW YORK, Jan. 7, 2026 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a...
Baird Medical Secures Regulatory Approvals in Pakistan and Vietnam
NEW YORK, Jan. 7, 2026 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a...
Pentixapharm Receives FDA Feedback for Phase 3 Diagnostic Study in Hypertension
Formal written minutes from the U.S. FDA confirms no major concerns identified for the planned Phase 3 PANDA study of...
GE HealthCare Recommends Shareholders Reject “Mini-Tender” Offer by Potemkin Limited
CHICAGO--(BUSINESS WIRE)--GE HealthCare Technologies Inc. (Nasdaq: GEHC) (“GE HealthCare”) announced today that it received notice on January 5, 2026, of...
Top Five Health Care Trends for 2026: How New Technology Is Transforming Patient Care
AUSTIN, Texas, Jan. 6, 2026 /PRNewswire/ -- From wearable devices that catch health issues sooner to artificial intelligence (AI) tools...
Base Molecular Resonance™ Technologies (BMRT) Achieves Historic Results in U.S. Government Sponsored Test
STUART, Fla., Jan. 6, 2026 /PRNewswire/ -- Base Molecular Resonance™ Technologies (BMRT) today announced the successful completion of a multi-day test supporting...
VivoSim Labs Appoints Amar Sethi, M.D., Ph.D. as Chief Scientific Officer
Distinguished drug-development and biomarker leader to advance NAMkind™ scientific strategy, translational insights, and next-generation toxicology platformsSAN DIEGO, Jan. 06, 2026...
Karlyn Dauplaise of Vizient Joins Next Gen Diagnostics as Chief Commercial Officer
CAMBRIDGE, Mass., Jan. 5, 2026 /PRNewswire/ -- Next Gen Diagnostics (NGD) today announced that Karlyn Dauplaise, a nationally recognized healthcare...
Karlyn Dauplaise of Vizient Joins Next Gen Diagnostics as Chief Commercial Officer
CAMBRIDGE, Mass., Jan. 5, 2026 /PRNewswire/ -- Next Gen Diagnostics (NGD) today announced that Karlyn Dauplaise, a nationally recognized healthcare...
Pharmaceutical Isolator Market Size to Reach USD 509 Million by 2031 | CAGR 2.4% – Valuates Reports
BANGALORE, India, Jan. 5, 2026 /PRNewswire/ -- Pharmaceutical Isolator Market SizeThe global Pharmaceutical Isolator market was valued at USD 432...